Chemomab Therapeutics Ltd ADR(CMMB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.02 | Insider Own | 4.53% | Shs Outstand | 7.3M | Perf Week | 12.62% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | -0.7% | Shs Float | 6.9M | Perf Month | -10.77% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 5.48% | Short Float | 0.2% | Perf Quarter | -28.4% |
| Income | -0.01B | P/S | - | EPS this Y | -11.11% | Inst Trans | 7.46% | Short Ratio | 0.14 | Perf Half Y | -27.87% |
| Sales | 0.00B | P/B | 0.97 | EPS next 5Y | - | ROA | -71.19% | Short Interest | 0.01M | Perf YTD | -29.7% |
| Book/sh | 1.2 | P/C | 1.26 | EPS past 3/5Y | 47.24% 43.73% | ROE | -82.74% | 52W High | -64.06% ($3.23) | Perf Year | -61.07% |
| Cash/sh | 0.92 | P/FCF | - | Sales past 3/5Y | - | ROIC | -87.57% | 52W Low | 26.07% ($0.92) | Perf 3Y | -60.81% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 56.99% | Gross Margin | - | Volatility(W/M) | 11.91% 10.29% | Perf 5Y | -97.11% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.41 | EPS Q/Q | 24.16% | Profit Margin | - | RSI (14) | 36.36 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.41 | Sales Q/Q | - | SMA20 | -5.05% ($1.22) | Beta | 0.8 | Target Price | $5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/19 | SMA50 | -39% ($1.9) | Rel Volume | 2.33 | Prev Close | $1.09 |
| Employees | 12 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 98% - | SMA200 | -33.86% ($1.75) | Avg Volume(3M) | 0.10M | Price | $1.16 |
| IPO | 2019/2/12 | Option/Short | No/Yes | Trades | 565 | Volume | 224,837 | Change | 6.42% |
🧫 This is a clinical-stage Israeli biotech developing antibody therapeutics targeting chronic inflammatory and fibrotic diseases. Its lead pipeline candidate, Nevokitug (CM-101), is a monoclonal antibody that blocks CCL24, a signaling protein involved in inflammation and fibrosis. The company is listed on Nasdaq as a micro-cap ADR, having aligned with the FDA on a Phase 3 trial design for primary sclerosing cholangitis (PSC).
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded more than usual. That is 233% of its average volume.
CMMB has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -11.1% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.1%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.5%.
Tap to view numbers
It ranks #513 of 597 in the industry
Based on market cap of $8M.
CMMB#513 Chemomab Therapeutics Ltd ADR $8M PER - 
MBRX#514 Moleculin Biotech Inc $8M PER - 
ENSC#515 Ensysce Biosciences Inc $8M PER - 
CURX#516 Curanex Pharmaceuticals Inc $8M PER - 
ACTU#517 Actuate Therapeutics Inc $8M PER - 
FAQ
What kind of company is CMMB?
CMMB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CMMB?
The market cap of CMMB is approximately $8M, ranking 5,491 within its sector.
What is the 52-week high and low for CMMB?
CMMB has recorded a 52-week high of $3.23 and a low of $0.92.
